Neuren Pharmaceuticals achieves breakthrough in Pitt Hopkins syndrome treatment
Neuren Pharmaceuticals (ASX: NEU) has announced promising top-line results from its Phase 2 clinical trial of NNZ-2591, aimed at treating children with Pitt Hopkins syndrome ... Read More